Advanced Liver Disease and Hepatitis B Clinic
2nd Thursday of each month 
12pm – 1:30pm Central Time  

Norman L. Sussman, M.D.  

Norman L. Sussman, M.D., FAASLD is the Project E.C.H.O. Medical Director and Associate Professor of Surgery in the Division of Abdominal Transplantation at Baylor College of Medicine. He also serves as Clinical Investigator/Sub-Investigator for Advanced Liver Therapies at St. Luke's Episcopal Hospital. Dr. Sussman is board certified in gastroenterology, internal medicine and transplant hepatology. Dr. Sussman earned his medical degree from the University of the Witwatersrand Medical School in Johannesburg, Republic of South Africa. His extensive training includes internships in internal medicine and surgery at Johannesburg General Hospital and senior house office positions in medicine and pediatrics at St. Charles' Hospital in London. Following his time in England, Dr. Sussman completed an internship and residency in internal medicine at St. Louis University Hospital in Missouri where he also served as chief resident. He completed a fellowship in gastroenterology at Washington University School of Medicine in St. Louis. Dr. Sussman clinical interests cover all aspects of liver disease. His research interests include assessment and management of acute liver failure, artificial liver support, new agents to treat viral hepatitis and complications of advanced cirrhosis. 


F.Blaine Hollinger, M.D.
Baylor College of Medicine

Dr. Hollinger has been actively involved in hepatitis research since joining the Department of Molecular Virology and Microbiology at Baylor College of Medicine in Houston, Texas in 1968 and the Department of Medicine (GI Section) in 1981. He is currently Professor of Medicine, Molecular Virology & Epidemiology and Director of the Eugene B. Casey Hepatitis Research Center. He also serves as Clinical Investigator/Sub-Investigator for Advanced Liver Therapies at Baylor St. Luke's Medical Center. He has been an advisor and consultant on program projects, grants, and contracts related to viral hepatitis for the National Institutes of Health and the Food and Drug Administration (FDA) and is a consultant to the Transfusion Transmitted Diseases Committee (TTD) of the American Association of Blood Banks (AABB) involved in the monitoring of emerging infectious disease agents that represent a potential threat to transfusion safety. He served on the Blood Products Advisory Committee (BPAC) for the FDA from 1995-2000, becoming its Chairman in 1997, and in 2009 accepted a reappointment to BPAC as its chairman until 2012.

Dr. Hollinger is an experienced researcher, hepatologist and international speaker who has engaged in a number of national, multicenter clinical trials and basic scientific projects related to viral hepatitis over the past 35 years. He has published over 265 peer-reviewed articles, books and chapters in the field of liver disease that includes the characterization and diagnosis of viral hepatitis agents, development of sensitive immunological assays, prophylaxis of hepatitis A and B including vaccine development, therapy of hepatitis B and C, studies on the immunopathogenesis and natural history of viral hepatitis, and the epidemiology of blood-borne pathogens and posttransfusion hepatitis.